Lexicon Pharmaceuticals (LXRX) Aandelenoverzicht
Lexicon Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf dat zich richt op het ontdekken, ontwikkelen en op de markt brengen van farmaceutische producten voor de behandeling van menselijke ziekten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
LXRX Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lexicon Pharmaceuticals, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$2.00 |
| 52 Week Hoogtepunt | US$2.68 |
| 52 Week Laag | US$1.06 |
| Bèta | 1.03 |
| 1 maand verandering | -14.89% |
| 3 maanden verandering | 4.17% |
| 1 Jaar Verandering | 73.91% |
| 3 jaar verandering | 42.86% |
| 5 jaar verandering | -58.85% |
| Verandering sinds IPO | -98.48% |
Recent nieuws en updates
Seeking Alpha • Aug 19
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets
Summary Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last update. Sotagliflozin, targeting HCM and T1D, is the primary value driver; the pivotal SONATA-HCM Phase III readout is expected in 2027, and an NDA re-filing for T1D before year-end. Regulatory and commercialization risks arguably outweigh clinical risk, especially for T1D, as the company would have to commit considerable resources to commercialization to maximize the value of sotagliflozin. Risk-adjusted fair value is $4.50–$4.75 per share, with major de-risking events over the next year making LXRX interesting for speculative investors. Read the full article on Seeking AlphaAnalyse-artikel • Aug 11
Analysts Have Made A Financial Statement On Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Second-Quarter Report
As you might know, Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) last week released its latest second-quarter, and...
Narratiefupdate • Aug 07
LXRX: Phase 3 HCM Trial Progress Will Likely Mask Weak Earnings Power
Analysts have lifted their fair value estimate for Lexicon Pharmaceuticals from $1.75 to $2.00, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that are reflected in recent Street research, including the latest price target increase reported this week. What’s in the News for Lexicon Pharmaceuticals Lexicon Pharmaceuticals reported completion of patient randomization in the pivotal Phase 3 SONATA HCM trial of sotagliflozin in symptomatic non obstructive and obstructive hypertrophic cardiomyopathy, with enrollment above the original 500 patient target across more than 130 sites in 20 countries.Recent updates
Seeking Alpha • Aug 19
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets
Summary Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last update. Sotagliflozin, targeting HCM and T1D, is the primary value driver; the pivotal SONATA-HCM Phase III readout is expected in 2027, and an NDA re-filing for T1D before year-end. Regulatory and commercialization risks arguably outweigh clinical risk, especially for T1D, as the company would have to commit considerable resources to commercialization to maximize the value of sotagliflozin. Risk-adjusted fair value is $4.50–$4.75 per share, with major de-risking events over the next year making LXRX interesting for speculative investors. Read the full article on Seeking AlphaAnalyse-artikel • Aug 11
Analysts Have Made A Financial Statement On Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Second-Quarter Report
As you might know, Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) last week released its latest second-quarter, and...Narratiefupdate • Aug 07
LXRX: Phase 3 HCM Trial Progress Will Likely Mask Weak Earnings Power
Analysts have lifted their fair value estimate for Lexicon Pharmaceuticals from $1.75 to $2.00, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that are reflected in recent Street research, including the latest price target increase reported this week. What’s in the News for Lexicon Pharmaceuticals Lexicon Pharmaceuticals reported completion of patient randomization in the pivotal Phase 3 SONATA HCM trial of sotagliflozin in symptomatic non obstructive and obstructive hypertrophic cardiomyopathy, with enrollment above the original 500 patient target across more than 130 sites in 20 countries.Narratiefupdate • Jul 03
LXRX: Index Additions Will Likely Mask Weak Revenue And Margin Outlook
Analysts have raised their fair value estimate for Lexicon Pharmaceuticals from $1.00 to $1.75, citing updated assumptions related to discount rates, revenue trends, profit margins, and a higher projected future P/E multiple. What’s in the News for Lexicon Pharmaceuticals Lexicon Pharmaceuticals is scheduled to present data on sotagliflozin in Type 1 diabetes and pilavapadin in diabetic peripheral neuropathic pain at the American Diabetes Association 2026 Scientific Sessions in New Orleans, with poster presentations on June 7, 2026, focusing on glycemic outcomes and pharmacokinetics.
Narratiefupdate • Jun 19
LXRX: Higher Future P/E And Novo Milestones Will Support Repricing
Analysts have adjusted their price target for Lexicon Pharmaceuticals stock upward by $0.80, with the move supported by updated fair value, profit margin and future P/E assumptions reflected in recent Street research. What's in the News for Lexicon Pharmaceuticals Lexicon Pharmaceuticals plans to present clinical data on sotagliflozin in Type 1 diabetes and pilavapadin in diabetic peripheral neuropathic pain at the American Diabetes Association 2026 Scientific Sessions in New Orleans, with poster presentations scheduled for June 7, 2026.Narratiefupdate • Jun 04
LXRX: Higher Future P/E And Novo Partnership Milestones Will Drive Repricing
Narrative Update: Lexicon Pharmaceuticals Analyst Price Target Shift Analysts have raised their price target on Lexicon Pharmaceuticals to $2.30 from $2.10. The change reflects updated views on the company that incorporate a slightly lower assumed profit margin and a higher future P/E multiple in the latest model.Narratiefupdate • May 11
LXRX: Phase 3 Pain Readiness And Partnership Prospects Will Drive Repricing
Analysts have lifted their fair value estimate for Lexicon Pharmaceuticals from $3.36 to $3.72, pointing to higher price targets from multiple firms and increased confidence in the pilavapadin program following recent clinical and regulatory progress. Analyst Commentary Recent Street research on Lexicon Pharmaceuticals highlights a mix of optimism around pilavapadin and caution around execution and deal timing, which feeds directly into fair value assumptions and risk assessments.Narratiefupdate • Apr 25
LXRX: Phase 3 Pain Program And Partnership Expectations Will Drive Repricing
Narrative Update Analysts have raised their price targets on Lexicon Pharmaceuticals to a range of about $2.30 to $6.00. They cite increased confidence in the pilavapadin program, particularly a higher assessed probability of success and expectations for a potential partnership on the Phase 3 ready asset.Narratiefupdate • Apr 06
LXRX: Phase 3 Pain Program Progress And Partnership Expectations May Support Upside
Analysts have raised their average price targets for Lexicon Pharmaceuticals, with moves such as Citi's shift from $2.10 to $2.30 and H.C. Wainwright's adjustment from $4 to $6, citing a higher assumed probability of success for pilavapadin and progress on clinical and regulatory work that they see as reducing program risk. Analyst Commentary Recent Street research on Lexicon Pharmaceuticals points to a generally constructive tone, with higher price targets linked to views on pilavapadin and the perceived risk profile of the pipeline.Narratiefupdate • Mar 21
LXRX: Phase 3 Pain Program And Key Partnership Potential May Drive Upside
Analysts have nudged the fair value estimate for Lexicon Pharmaceuticals higher to $3.36 from $3.32, reflecting updated assumptions around revenue growth, profit margins and future P/E multiples following recent price target increases to $2.30 at one firm and $6 at another. Analyst Commentary Recent research updates offer a mixed picture on Lexicon Pharmaceuticals, with higher price targets tied closely to progress on its pipeline, particularly pilavapadin, and expectations around future execution.Narratiefupdate • Mar 07
LXRX: Phase 3 Pain Program And Partnership Prospects Will Support Future Upside
Analysts have raised their price targets on Lexicon Pharmaceuticals, with one moving from $4 to $6, citing a higher assumed probability of success for pilavapadin and the potential for an important partnership on this Phase 3 ready program. Analyst Commentary Bullish Takeaways Bullish analysts see the higher assumed probability of success for pilavapadin, at 30% versus the prior 15%, as a key input to higher valuation for Lexicon, particularly as the program is described as Phase 3 ready.Narratiefupdate • Feb 21
LXRX: Phase 3 Pain Program Progress Will Support Stronger Future Earnings Power
Analysts have raised their price target on Lexicon Pharmaceuticals by $0.20, citing updated assumptions around discount rates, profit margin expectations, and future P/E levels that refine their view of the stock's risk and earnings power. Analyst Commentary Analysts raising the price target by $0.20 are fine tuning their models rather than making a sweeping call, and their commentary gives you a sense of what they think could go right or wrong from here.Narratiefupdate • Jan 27
LXRX: Phase 3 Pain Program Progress Will Support Higher Future Earnings Power
Analysts have nudged their price target for Lexicon Pharmaceuticals higher, with fair value moving from US$2.75 to US$2.92 as they factor in updated views on discount rates, revenue growth, profit margins and future P/E multiples. Analyst Commentary Analysts updating their models around Lexicon Pharmaceuticals are using the new fair value estimate of US$2.92 as a reference point, linking it to assumptions on discount rates, revenue trajectories, margins and future P/E levels.Analyse-artikel • Jan 22
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up
Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have had a really impressive month, gaining 28% after a shaky...Analyse-artikel • Dec 18
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse-artikel • Oct 02
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%
Despite an already strong run, Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have been powering on, with a gain...Narratiefupdate • Aug 22
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Lexicon Pharmaceuticals' price target was revised down to $2.75 as analysts weigh mixed signals: strong Q2 results and management confidence against heightened reliance on positive upcoming PROGRESS trial data as a near-term share catalyst. Analyst Commentary Upward price target revision follows recent Q2 results exceeding expectations.Narratiefupdate • Aug 07
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Despite a sharp downgrade in revenue growth forecasts, Lexicon Pharmaceuticals’ consensus analyst price target has increased notably, supported by a lower future P/E ratio and now stands at $3.05. What's in the News Post-hoc analysis of clinical data showed sotagliflozin reduced hypoglycemia events without increased risk across kidney function subgroups in type 1 diabetes patients using optimized insulin therapy.Analyse-artikel • Jul 28
There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump
Despite an already strong run, Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have been powering on, with a gain...Analyse-artikel • Jun 13
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%
Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have continued their recent momentum with a 31% gain in the last...Analyse-artikel • May 19
Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts
Shareholders in Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) may be thrilled to learn that the analysts have just...Analyse-artikel • May 17
Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates
Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) investors will be delighted, with the company turning in some strong...
Nieuw narratief • Apr 01
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.Seeking Alpha • Mar 28
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Summary Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted focus to becoming a clinical development-focused company. Lexicon's Phase 2b neuropathy trial technically failed but the company plans to advance to Phase 3 trials. With $238 million in cash, Lexicon has financial runway into early 2027 despite monthly burn of $7 million. I upgraded my rating from "Sell" to "Hold" but remain cautious until Lexicon establishes signs of sustainable revenue generation in the future. Read the full article on Seeking AlphaAnalyse-artikel • Mar 26
Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%
The Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Oct 16
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
Summary Lexicon's Inpefa faces fierce competition from established SGLT2 inhibitors, like Farxiga and Jardiance, making market penetration difficult. Inpefa’s early commercial results are underwhelming, with Q2 revenue of only $1.6 million and rising SG&A costs. Lexicon has pivoted from heart failure to type 1 diabetes, where sotagliflozin could be the first SGLT2 approved for T1D in the U.S. The company’s pipeline includes LX9211 for diabetic peripheral neuropathic pain, though Phase 2 results indicate mixed efficacy and safety concerns. Given strong competition, limited market penetration, and pipeline risks, Lexicon presents a high-risk, low-reward investment opportunity. Read the full article on Seeking AlphaAnalyse-artikel • Aug 08
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Aug 03
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Summary Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and cash reserves provide opportunities for Lexicon to improve commercial execution and drive revenue growth, and improved patient access and payer coverage are 2H'24 priorities. The company has resubmitted its application for Zynquista in Type 1 diabetes, a commercially significant opportunity, but one where regulatory and execution risk are still very present. Lexicon's pipeline is getting more interesting, with LX9211 in diabetic neuropathy and a new candidate for obesity and/or metabolic disease in preclinical testing, but effectively commercializing Inpefa remains critical. Lexicon shares appear undervalued on the basis of Inpefa's commercial opportunity and the risk-adjusted opportunities in Type 1 diabetes, diabetic neuropathy, and hypertrophic cardiomyopathy, but execution risk is very high. Read the full article on Seeking AlphaRendement voor aandeelhouders
| LXRX | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -10.7% | -3.4% | -1.0% |
| 1Y | 73.9% | 44.7% | 14.1% |
Rendement versus industrie: LXRX overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 44.7 % opleverde.
Rendement versus markt: LXRX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 14.1 %.
Prijsvolatiliteit
| LXRX volatility | |
|---|---|
| LXRX Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: LXRX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van LXRX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1995 | 81 | Mike Exton | www.lexpharma.com |
Lexicon Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf dat zich richt op het ontdekken, ontwikkelen en op de markt brengen van farmaceutische producten voor de behandeling van menselijke ziekten. Het bedrijf ontwikkelt sotagliflozin, een oraal toegediend geneesmiddel op basis van kleine moleculen voor de behandeling van hypertrofische cardiomyopathie, en ZYNQUISTA (sotagliflozin) voor de behandeling van type 1 diabetes. Het bedrijf verkoopt ook INPEFA (sotagliflozin), een eenmaal daags oraal tablet om het risico op cardiovasculair overlijden, ziekenhuisopname voor hartfalen en spoedeisend bezoek voor hartfalen te verminderen bij volwassenen met hartfalen of diabetes type 2, CKD en andere cardiovasculaire risicofactoren.
Lexicon Pharmaceuticals, Inc. Samenvatting
| LXRX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$898.81m |
| Inkomsten(TTM) | -US$61.12m |
| Inkomsten(TTM) | US$41.47m |
21.5x
P/S-verhouding-14.6x
Koers/WinstverhoudingIs LXRX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| LXRX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$41.47m |
| Kosten van inkomsten | US$5.80m |
| Brutowinst | US$35.67m |
| Overige uitgaven | US$96.79m |
| Inkomsten | -US$61.12m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.14 |
| Brutomarge | 86.02% |
| Nettowinstmarge | -147.38% |
| Schuld/Eigen Vermogen Verhouding | 29.5% |
Hoe presteerde LXRX op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/11 14:36 |
| Aandelenkoers aan het einde van de dag | 2026/09/11 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Lexicon Pharmaceuticals, Inc. wordt gevolgd door 12 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Andrew Tsai | Jefferies LLC |